Want to see GLUE full AI Analyst Report?
GLUE Stock Chart & Stats
$19.78
-$0.20(-2.99%)
At close: 4:00 PM EST
$19.78
-$0.20(-2.99%)
Day’s Range― - ―
52-Week Range$4.12 - $25.77
Previous CloseN/A
Volume283.19K
Average Volume (3M)1.53M
Market Cap
$2.07B
Enterprise Value$1.02K
Total Cash (Recent Filing)$666.22M
Total Debt (Recent Filing)$39.06M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding84,479,416
10 Day Avg. Volume1,295,287
30 Day Avg. Volume1,527,401
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)5.59
Price to Sales (P/S)10.53
P/FCF Ratio-47.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.80Price Target Upside70.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$44.46M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow debt-to-equity (~0.07 TTM) and expanding total assets give Monte Rosa financing flexibility typical biotechs need to fund R&D and partnerships. This durable balance-sheet strength reduces near-term refinancing risk and supports continued investment in clinical programs over months.
High Gross MarginsVery high gross margins (92% in 2025; 80% TTM) reflect a low-cost, scalable small-molecule discovery and licensing model. Durable margin economics improve long-term program economics, meaning revenue from deals or products can more effectively cover fixed R&D and accelerate value capture.
Proprietary PlatformA proprietary molecular glue degrader platform is a durable competitive asset: it concentrates scientific expertise, shortens discovery cycles, and enhances partnership and licensing appeal. Structural IP and platform know-how underlie repeatable program creation and long-term pipeline value.
Bears Say
Large Net LossesA sustained TTM net loss of ~$130M indicates the company remains unprofitable and reliant on external financing or partner cash. Persistent operating losses can erode equity, force dilutive financings, and constrain the ability to self-fund later-stage trials or commercial activities over the medium term.
Revenue VolatilityA sharp TTM revenue decline (~65%) highlights reliance on lump-sum collaboration receipts and milestone timing. This structural volatility complicates multi-period budgeting, increases program funding uncertainty, and heightens dependence on partner decisions for sustained revenue generation.
Cash Flow InstabilityReturn to negative operating (-$14.7M) and free cash flow (-$19.7M) in TTM shows inconsistent cash generation. Durable program execution requires steady funding; this cash-flow volatility raises the likelihood of future equity raises or partnership dependence, creating execution and dilution risk.
Monte Rosa Therapeutics News
GLUE FAQ
What was Monte Rosa Therapeutics, Inc.’s price range in the past 12 months?
Monte Rosa Therapeutics, Inc. lowest stock price was $4.12 and its highest was $25.77 in the past 12 months.
What is Monte Rosa Therapeutics, Inc.’s market cap?
Monte Rosa Therapeutics, Inc.’s market cap is $2.07B.
When is Monte Rosa Therapeutics, Inc.’s upcoming earnings report date?
Monte Rosa Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Monte Rosa Therapeutics, Inc.’s earnings last quarter?
Monte Rosa Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.062.
Is Monte Rosa Therapeutics, Inc. overvalued?
According to Wall Street analysts Monte Rosa Therapeutics, Inc.’s price is currently Undervalued.
Does Monte Rosa Therapeutics, Inc. pay dividends?
Monte Rosa Therapeutics, Inc. does not currently pay dividends.
What is Monte Rosa Therapeutics, Inc.’s EPS estimate?
Monte Rosa Therapeutics, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Monte Rosa Therapeutics, Inc. have?
Monte Rosa Therapeutics, Inc. has 84,479,416 shares outstanding.
What happened to Monte Rosa Therapeutics, Inc.’s price movement after its last earnings report?
Monte Rosa Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -2.845%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GLUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monte Rosa Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.80 (70.88% Upside)
$33.80 (70.88% Upside)
Blogger Sentiment
Neutral
GLUE Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 666.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $631.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
316.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
87.29%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
GLUE Stock 12 Month Forecast
Average Price Target
$33.80
▲(70.88% Upside)
Technical Analysis
CytomX Therapeutics
―
Fulcrum Therapeutics
―
Monopar Therapeutics Inc
―
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.96% Insiders
15.12% Mutual Funds
0.04% Other Institutional Investors
59.11% Public Companies and
Individual Investors